Reports - Adeno-associated Virus (AAV) Vector-based Gene Therapy Market
HealthcareAdeno-associated Virus (AAV) Vector-based Gene Therapy Market
Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Size and Projected Growth Through 2035 by Disease Type (Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology) by Vector Serotype (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9) by Administration Route (Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral) by End User (Hospitals, Research Institutes, Biopharmaceutical Companies) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2021 - 2035 (USD Million)
3. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Disease Type
3.1. By Hematological Malignancies
3.2. By Neurological Disorders
3.3. By Cardiovascular Diseases
3.4. By Ophthalmic Diseases
3.5. By Oncology
4. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Vector Serotype
4.1. By AAV1
4.2. By AAV2
4.3. By AAV5
4.4. By AAV6
4.5. By AAV8
4.6. By AAV9
5. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Administration Route
5.1. By Intravenous
5.2. By Intramuscular
5.3. By Subcutaneous
5.4. By Intraocular
5.5. By Intracerebral
6. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by End User
6.1. By Hospitals
6.2. By Research Institutes
6.3. By Biopharmaceutical Companies
7. Global Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by region
7.1. North America
7.2. Europe
7.3. Asia Pacific
7.4. Latin America
7.5. Middle East & Africa
8. Market comparative analysis
Chapter 4 North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2021 - 2035 (USD Million)
3. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Disease Type
3.1. By Hematological Malignancies
3.2. By Neurological Disorders
3.3. By Cardiovascular Diseases
3.4. By Ophthalmic Diseases
3.5. By Oncology
4. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Vector Serotype
4.1. By AAV1
4.2. By AAV2
4.3. By AAV5
4.4. By AAV6
4.5. By AAV8
4.6. By AAV9
5. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Administration Route
5.1. By Intravenous
5.2. By Intramuscular
5.3. By Subcutaneous
5.4. By Intraocular
5.5. By Intracerebral
6. North America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by End User
6.1. By Hospitals
6.2. By Research Institutes
6.3. By Biopharmaceutical Companies
Chapter 5 Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2021 - 2035 (USD Million)
3. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Disease Type
3.1. By Hematological Malignancies
3.2. By Neurological Disorders
3.3. By Cardiovascular Diseases
3.4. By Ophthalmic Diseases
3.5. By Oncology
4. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Vector Serotype
4.1. By AAV1
4.2. By AAV2
4.3. By AAV5
4.4. By AAV6
4.5. By AAV8
4.6. By AAV9
5. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Administration Route
5.1. By Intravenous
5.2. By Intramuscular
5.3. By Subcutaneous
5.4. By Intraocular
5.5. By Intracerebral
6. Europe Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by End User
6.1. By Hospitals
6.2. By Research Institutes
6.3. By Biopharmaceutical Companies
Chapter 6 Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2021 - 2035 (USD Million)
3. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Disease Type
3.1. By Hematological Malignancies
3.2. By Neurological Disorders
3.3. By Cardiovascular Diseases
3.4. By Ophthalmic Diseases
3.5. By Oncology
4. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Vector Serotype
4.1. By AAV1
4.2. By AAV2
4.3. By AAV5
4.4. By AAV6
4.5. By AAV8
4.6. By AAV9
5. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Administration Route
5.1. By Intravenous
5.2. By Intramuscular
5.3. By Subcutaneous
5.4. By Intraocular
5.5. By Intracerebral
6. Asia Pacific Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by End User
6.1. By Hospitals
6.2. By Research Institutes
6.3. By Biopharmaceutical Companies
Chapter 7 Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2021 - 2035 (USD Million)
3. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Disease Type
3.1. By Hematological Malignancies
3.2. By Neurological Disorders
3.3. By Cardiovascular Diseases
3.4. By Ophthalmic Diseases
3.5. By Oncology
4. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Vector Serotype
4.1. By AAV1
4.2. By AAV2
4.3. By AAV5
4.4. By AAV6
4.5. By AAV8
4.6. By AAV9
5. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Administration Route
5.1. By Intravenous
5.2. By Intramuscular
5.3. By Subcutaneous
5.4. By Intraocular
5.5. By Intracerebral
6. Latin America Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by End User
6.1. By Hospitals
6.2. By Research Institutes
6.3. By Biopharmaceutical Companies
Chapter 8 Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - Segment Analysis
1. Overview
2. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Disease Type
3.1. By Hematological Malignancies
3.2. By Neurological Disorders
3.3. By Cardiovascular Diseases
3.4. By Ophthalmic Diseases
3.5. By Oncology
4. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Vector Serotype
4.1. By AAV1
4.2. By AAV2
4.3. By AAV5
4.4. By AAV6
4.5. By AAV8
4.6. By AAV9
5. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by Administration Route
5.1. By Intravenous
5.2. By Intramuscular
5.3. By Subcutaneous
5.4. By Intraocular
5.5. By Intracerebral
6. Middle East & Africa Adeno-associated Virus (AAV) Vector-based Gene Therapy Market - by End User
6.1. By Hospitals
6.2. By Research Institutes
6.3. By Biopharmaceutical Companies
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Pfizer
2. BioMarin Pharmaceutical
3. Sarepta Therapeutics
4. Takeda
5. UniQure
6. Regenxbio
7. Adverum Biotechnologies
8. Spark Therapeutics (Roche)
9. Astellas Pharma
10. Bayer
11. Ultragenyx Pharmaceutical
12. Audentes Therapeutics (Astellas)
13. Homology Medicines
14. GenSight Biologics
15. Sangamo Therapeutics.
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By